|
Oct 10
|
InnoCare’s Phase II psoriasis therapy trial meets primary endpoint
|
|
Oct 9
|
InnoCare Announces Phase II Study Results of TYK2 Inhibitor ICP-488 Meet Primary Endpoint in Psoriasis Patients
|
|
Aug 20
|
InnoCare Releases 2024 Interim Results and Business Highlights
|
|
Jul 24
|
InnoCare Announces First Subject Dosed in Clinical Trial of TYK2 Inhibitor ICP-332 in the U.S.
|
|
Jun 14
|
Data of InnoCare’s Robust Pipelines Presented at the European Hematology Association (EHA) 2024 Hybrid Congress
|
|
Jan 22
|
InnoCare Announces First Prescription of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Under Greater Bay Area’s Early Access Program
|
|
Jan 16
|
InnoCare Announces Clearance of Clinical Trial of BCL2 Inhibitor ICP-248 by U.S. FDA
|
|
Dec 11
|
Latest Data of InnoCare’s Oncology Pipelines Presented at the 65th Annual Meeting of ASH
|
|
Nov 15
|
10 Studies on InnoCare’s Oncology Pipelines Selected at the Upcoming 65th Annual Meeting of ASH
|